A STIR nucleic acid drug delivery system for stirring phenotypic switch of microglia in Parkinson’s disease treatments

[1]  Meng Zheng,et al.  Back Cover: Brain co‐delivery of first‐line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy (EXP2 4/2022) , 2022, Exploration.

[2]  Xiaoding Xu,et al.  Nucleus‐specific RNAi nanoplatform for targeted regulation of nuclear lncRNA function and effective cancer therapy , 2022, Exploration.

[3]  Mei-xia Zhao,et al.  Aminophosphate precursors for the synthesis of near‐unity emitting InP quantum dots and their application in liver cancer diagnosis , 2022, Exploration.

[4]  X. Jing,et al.  Indocyanine green potentiated paclitaxel nanoprodrugs for imaging and chemotherapy , 2022, Exploration.

[5]  Meng Zheng,et al.  Brain co‐delivery of first‐line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy , 2022, Exploration.

[6]  L. Parr-Brownlie,et al.  Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson’s disease , 2022, Ageing Research Reviews.

[7]  Weiqi Wang,et al.  Intranasal Administration of Self-Oriented Nanocarriers Based on Therapeutic Exosomes for Synergistic Treatment of Parkinson's Disease. , 2022, ACS nano.

[8]  Jun Yang,et al.  Self‐Catalytic Small Interfering RNA Nanocarriers for Synergistic Treatment of Neurodegenerative Diseases , 2021, Advanced materials.

[9]  K. Pahan,et al.  Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo , 2021, Nature Communications.

[10]  Xi-xiu Xie,et al.  The Role of α-Synuclein Oligomers in Parkinson’s Disease , 2020, International journal of molecular sciences.

[11]  Alexander von Ehr,et al.  Inhibition of Microglial TGFβ Signaling Increases Expression of Mrc1 , 2020, Frontiers in Cellular Neuroscience.

[12]  Jun Yang,et al.  An “Amyloid‐β Cleaner” for the Treatment of Alzheimer's Disease by Normalizing Microglial Dysfunction , 2019, Advanced science.

[13]  A. Roig,et al.  MRI/Photoluminescence Dual-Modal Imaging Magnetic PLGA Nanocapsules for Theranostics , 2019, Pharmaceutics.

[14]  S. Rai,et al.  NF-κB-Mediated Neuroinflammation in Parkinson’s Disease and Potential Therapeutic Effect of Polyphenols , 2019, Neurotoxicity Research.

[15]  T. Motawi,et al.  Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson’s disease mice model , 2019, Molecular and Cellular Biochemistry.

[16]  Yue-Ying Chen,et al.  Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood–brain barrier and target glioma , 2019, AMB Express.

[17]  P. Calabresi,et al.  Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease , 2019, Nature Communications.

[18]  N. Stefanova,et al.  Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies , 2019, Front. Cell. Neurosci..

[19]  Ginpreet Kaur,et al.  Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease , 2019, Journal of Neuroimmunology.

[20]  S. Chankeshwara,et al.  Surface Charge-Dependent Cellular Uptake of Polystyrene Nanoparticles , 2018, Nanomaterials.

[21]  Anjali Sharma,et al.  Effect of mannose targeting of hydroxyl PAMAM dendrimers on cellular and organ biodistribution in a neonatal brain injury model , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Y. Chern,et al.  Microglial Lectins in Health and Neurological Diseases , 2018, Front. Mol. Neurosci..

[23]  J. Weng,et al.  Traceable Nanoparticles with Dual Targeting and ROS Response for RNAi‐Based Immunochemotherapy of Intracranial Glioblastoma Treatment , 2018, Advanced materials.

[24]  Ruiyuan Liu,et al.  Delivery systems for theranostics in neurodegenerative diseases , 2018, Nano Research.

[25]  G. Ma,et al.  Positively Charged Polyprodrug Amphiphiles with Enhanced Drug Loading and Reactive Oxygen Species-Responsive Release Ability for Traceable Synergistic Therapy. , 2018, Journal of the American Chemical Society.

[26]  S. Tüzmen,et al.  Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran , 2017, Pharmacogenomics and personalized medicine.

[27]  N. Sibson,et al.  Anti-inflammatory Microglia/Macrophages As a Potential Therapeutic Target in Brain Metastasis , 2017, Front. Oncol..

[28]  R. Wade-Martins,et al.  Alpha-synuclein oligomers: a new hope , 2017, Acta Neuropathologica.

[29]  Hongxu Lu,et al.  Direct Correlation Between Zeta Potential and Cellular Uptake of Poly(methacrylic acid) Post‐Modified with Guanidinium Functionalities , 2016 .

[30]  P. Michel,et al.  Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways , 2016, Neurotoxicity Research.

[31]  Qing Yao,et al.  Amphiphilic poly(amino acid) based micelles applied to drug delivery: the in vitro and in vivo challenges and the corresponding potential strategies. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[32]  唐宇,et al.  Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases , 2015 .

[33]  W. Le,et al.  Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases , 2016, Molecular Neurobiology.

[34]  He-Jin Lee,et al.  Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases , 2014, Nature Reviews Neurology.

[35]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[36]  S. Nam,et al.  Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models , 2012, Journal of Neuroinflammation.

[37]  Michael J Morgan,et al.  Crosstalk of reactive oxygen species and NF-κB signaling , 2011, Cell Research.

[38]  Howard E. Gendelman,et al.  Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[39]  Sudipta Seal,et al.  Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. , 2007, Biomaterials.

[40]  Y. Changlong,et al.  NF-κBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1β-induced and TNF-α-induced chondrocytes , 2006 .

[41]  S. Akira,et al.  Toll-like receptors in innate immunity. , 2004, International immunology.

[42]  T. Sherer,et al.  Mechanistic Approaches to Parkinson's Disease Pathogenesis , 2002, Brain pathology.